Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio de CTX-009 en pacientes adultos con cáncer colorrectal metastásico (COMPANION-003)

1 de septiembre de 2026 actualizado por: Compass Therapeutics

Un estudio de fase 2 de CTX-009 en pacientes adultos con cáncer colorrectal metastásico que han recibido dos o tres regímenes previos de quimioterapia sistémica

This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer.

A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

49

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Arkansas
      • Hot Springs, Arkansas, Estados Unidos, 71913
        • Genesis Cancer and Blood Institute
    • Florida
      • Fort Myers, Florida, Estados Unidos, 33916
        • Florida Cancer Specialists & Research Institute - South
      • St. Petersburg, Florida, Estados Unidos, 33705
        • Florida Cancer Specialists & Research Institute - North
    • New Jersey
      • New Brunswick, New Jersey, Estados Unidos, 08903
        • Rutgers Cancer Institute of New Jersey
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43219
        • Zangmeister Cancer Center
    • Tennessee
      • Nashville, Tennessee, Estados Unidos, 37203
        • SCRI Oncology Partners
    • Texas
      • Dallas, Texas, Estados Unidos, 75230
        • Mary Crowley Cancer Research

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. 18 years of age or older

  2. Histologically or cytologically confirmed metastatic or recurrent colorectal cancers

  3. The primary tumor must have been resected > 3 months prior to planned C1D1.

  4. Patients who experienced progressive disease or relapse after receiving two or three prior lines of systemic therapy in the locally advanced or metastatic setting. Prior lines of systemic treatment must have included at least one fluoropyrimidine, oxaliplatin, irinotecan, and bevacizumab containing chemotherapy regimen (in any combination and may have been administered in the neoadjuvant setting).

    1. Patients whose tumor is not right sided and RAS wild type must also have received an anti-epidermal growth factor receptor (EGFR) therapy.
    2. Patients with tumors harboring mutations or other alterations for which there are available targeted therapies (e.g. BRAF V600E, HER2-positive, MSI-H/dMMR, etc.) must have also received the relevant approved targeted therapies.
    3. If patient received peri-operative treatment (neoadjuvant and/or adjuvant), please consult the Sponsor Medical Monitor for review of prior treatment lines.
  5. At least one lesion measurable as defined by RECIST v1.1

  6. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

  7. Predicted life expectancy of at least 12 weeks

  8. Adequate hepatic and renal function within 14 days of C1D1 as described below:

    1. Total bilirubin ≤ 1.5 X upper limit of normal (ULN)
    2. Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) ≤ 3.0 X ULN (≤ 5x ULN in case of hepatic metastasis)
    3. Estimated creatinine clearance ≥ 30 mL/min based on Cockcroft-Gault estimated creatinine clearance
    4. Urine protein ≤ 1+ by spot urinalysis (or, if > 1+ then 24 hr urine protein <1.0 g/24 hr)
  9. Female patients who are women of childbearing potential (WCBP) must have a negative pregnancy test (serum-human chorionic gonadotropin [hCG] or urine-hCG) at Screening within 14 days of C1D1

  10. Female patients must be surgically sterile (or have a monogamous partner who is surgically sterile) or be at least 2 years postmenopausal or commit to use 2 acceptable forms of birth control (defined as the use of an intrauterine device (IUD), a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 4 months following the last dose of study treatment. Male patients must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study and for 4 months following the last dose of study treatment

  11. Signed and dated Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved Informed Consent Form (ICF) before any protocol-directed screening procedures are performed

Exclusion Criteria:

  1. From the time point of signed informed consent,

    1. Less than 4 weeks have elapsed since patients had a surgery or major procedure
    2. Less than 2 weeks have elapsed from the last treatment date since patients had any radiation therapy
  2. Prior to planned C1D1,

    1. Less than 4 weeks have elapsed since patients had chemotherapy or targeted therapy for colorectal cancer
    2. Less than 4 weeks have elapsed since patients had anticancer immunotherapy or investigational drug treatment
  3. A history of the following cardiovascular diseases in past 5 years may be exclusionary, as determined by the Sponsor Medical Monitor:

    1. Congestive heart failure that corresponds to Class II or a higher class under New York Heart Association (NYHA) classification or less than 50% of left ventricular ejection fraction (LVEF)
    2. Uncontrolled hypertension (systolic blood pressure [SBP]/diastolic blood pressure [DBP] > 140/90 mmHg) (e.g., patient with SBP/DBP > 140/90 mmHg despite the best care including anti-hypertensive medications)
    3. Patients with a history of hypertensive crisis or pre-existing hypertensive encephalopathy
    4. Pulmonary hypertension
    5. Myocardial infarction
    6. Uncontrolled arrhythmia
    7. Unstable angina
    8. Patients with any significant vascular diseases (e.g., aortic aneurysm requiring surgery or recent peripheral artery thrombosis) within 6 months prior to the initial treatment of the investigational product
  4. Symptomatic or uncontrolled central nervous system (CNS) metastasis (However, patients with asymptomatic CNS metastasis can participate provided that systemic corticosteroid treatment was discontinued at least 4 weeks prior to screening and that the patient is radiologically and neurologically stable or improving)

  5. A history of the following hemorrhage-related or gastroenterological disease:

    1. Active hemorrhage, hemorrhagic diathesis, coagulopathy or tumor invasion into great arteries
    2. History of clinically significant and active (within 6 months) gastroenterological disease, such as peptic ulcer, gastrointestinal (GI) bleeding, GI or non-GI fistula, perforation, abdominal abscess, clinical symptoms and signs of GI obstruction, need for parenteral hydration or nutrition, or inflammatory bowel disease.
  6. Patients who received antiplatelet drugs (aspirin, clopidogrel, etc.) or anticoagulant drugs (warfarin, heparin, direct thrombin inhibitors, etc.) within 2 weeks prior to C1D1, or are expected to need those drugs during the clinical study.

  7. Patients requiring continuous treatment with systemic non-steroidal anti-inflammatory drugs (NSAIDs) or systemic corticosteroids (the following cases are permitted):

    1. NSAIDs: Up to 3 consecutive days' use is permitted
    2. Corticosteroids: Topical use of corticosteroid, such as topical intra-articular injection, intranasal administration, eye drops, inhaler, etc., or temporary systemic corticosteroid use for treatment and prevention of patient's contrast media allergy, or adverse event, is permitted
  8. Severe infection requiring systemic antibiotics, antivirus drugs, etc., or other uncontrolled acute active infectious diseases

  9. Patients with evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Inactive hepatitis B carriers who tested HBsAg positive may enroll provided that the patient's liver function values are normal. Also, patients with chronic HBV infection which has been controlled by the site's treatment guideline may enroll. HCV patients showing sustained viral response or patients with immunity to HBV infection may enroll

  10. Patients with other severe diseases or uncontrolled illnesses that warrant the exclusion from the study (permitted only if medically controlled) including but not limited to:

    1. Pre-existing hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 28 days prior to screening
    2. Major, unhealed injury, active ulcer or untreated fracture
    3. History of cerebrovascular incident (ischemic or hemorrhagic stroke), transient ischemic attack or subarachnoid hemorrhage within 6 months prior to screening
    4. Moderate to severe ascites and/or pleural effusion
  11. Clinically significant abnormal electrocardiography (ECG) findings or history determined as clinically significant by the Investigator

  12. QT interval (Fridericia's formula) (QTcF) interval > 450 msec at the time of screening

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Tratamiento CTX-009

IV infusion administered on day 1 and 15 of every 28-day cycle

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Overall Response Rate
Periodo de tiempo: From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)

Percentage of patients whose best overall response is assessed as complete response (CR) or partial response (PR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: >=30% decrease in the sum of the longest diameter of target lesions.

From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Disease Control Rate
Periodo de tiempo: From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)

Percentage of all treated patients whose best overall response was complete response (CR), partial response (PR), or stable disease (SD) for a minimum of 6 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: >=30% decrease in the sum of the longest diameter of target lesions; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease.

From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)
Duration of Response
Periodo de tiempo: From first date of complete or partial response to first date of disease progression or death (up to 15.4 weeks)

Time from the CT or MRI that first confirmed complete (CR) or partial response PR) to the CT or MRI that first confirmed progression of disease progression (PD). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by CT or MRI: CR: disappearance of all target lesions; PR: >=30% decrease in the sum of the longest diameter of target lesions; PD = 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

From first date of complete or partial response to first date of disease progression or death (up to 15.4 weeks)
Progression-free Survival
Periodo de tiempo: From first dose of CTX-009 to disease progression or death (up to 5.8 months)

Time from first dose of CTX-009 to progression of disease or death. Progression of diseases is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

From first dose of CTX-009 to disease progression or death (up to 5.8 months)
Overall Survival
Periodo de tiempo: From first dose of CTX-009 to death (up to 17.8 months)

Time from first dose of CTX-009 to death

From first dose of CTX-009 to death (up to 17.8 months)
Incidence of Treatment-emergent Adverse Events (TEAEs) and Changes in Clinical Abnormalities
Periodo de tiempo: From the first CTX-009 dose to 30 days after the last CTX-009 dose (average 20 weeks) for TEAEs, from the first CTX-009 dose to 60 days after the last CTX-009 dose (average 25 weeks) for lab tests, vital signs, and ECGs.

TEAE is defined by occurrence of an adverse event that started or worsened in severity on or after the first dose of CTX-009 through 30 days after the last dose of CTX-009. Change in clinical abnormalities is defined as an increase in abnormality grade in a laboratory result, vital sign, or ECG parameter from predose result to worst postdose result (graded according to the Common Terminology Criteria for Adverse Events v5.0 for all analytes except for brain natriuretic peptide and troponin subtypes, which are interpreted in reference to the laboratory reference range for each), a post-baseline potentially clinically significant vital sign abnormality, or a post-baseline potentially clinically significant ECG abnormality.

From the first CTX-009 dose to 30 days after the last CTX-009 dose (average 20 weeks) for TEAEs, from the first CTX-009 dose to 60 days after the last CTX-009 dose (average 25 weeks) for lab tests, vital signs, and ECGs.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Director de estudio: Minori Rosales, MD, PhD, Compass Therapeutics

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

8 de diciembre de 2022

Finalización primaria (Actual)

15 de mayo de 2025

Finalización del estudio (Actual)

15 de mayo de 2025

Fechas de registro del estudio

Enviado por primera vez

22 de agosto de 2022

Primero enviado que cumplió con los criterios de control de calidad

22 de agosto de 2022

Publicado por primera vez (Actual)

24 de agosto de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

25 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

1 de septiembre de 2026

Última verificación

1 de junio de 2025

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir